Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab plus /- chemotherapy in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Ricciuti, Biagio
Champagne, Christine
Jones, Greg
Lazarus, Tadd Scott
Adeni, Anika E.
Cheng, Michael L.
Oxnard, Geoffrey R.
Awad, Mark M.
机构：
[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Inivata, Cambridge, England
[4] Inivata Inc, Austin, TX USA
[5] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3518
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
    Dempke, Wolfram C. M.
    Fenchel, Klaus
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (05) : 538 - 542
  • [33] Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
    Guo, Yimeng
    Jia, Junting
    Hao, Zhiying
    Yang, Jing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [34] Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China
    Wang, Hao
    Liao, Li
    Xu, Yuan
    Long, Yunchun
    Wang, Ye
    Zhou, Yujie
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations
    F. Grossi
    A. Brianti
    C. Defferrari
    P. Pronzato
    memo - Magazine of European Medical Oncology, 2008, 1 (1) : 13 - 16
  • [36] Chemotherapy plus bevacizumab in the first-line tratment of non-small cell lung cancer: benefits, risks and limitations
    Grossi, F.
    Brianti, A.
    Defferrari, C.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2008, 1 (01) : 13 - 16
  • [37] Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
    Roboubi, Amytis
    Wasielewski, Eric
    Bordier, Soraya
    Turlotte, Amelie
    Pavaut, Geoffrey
    Scherpereel, Arnaud
    Cortot, Alexis
    Gauvain, Clement
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [38] Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer
    Shields, Misty Dawn
    Chen, Kevin
    Dutcher, Giselle
    Patel, Ishika
    Pellini, Bruna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [39] Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice
    Cho, Byoung Chul
    Loong, Herbert H. F.
    Tsai, Chun-Ming
    Teo, Man Lung P.
    Kim, Hye Ryun
    Lim, Sun Min
    Jain, Suyog
    Olsen, Steve
    Park, Keunchil
    CURRENT ONCOLOGY, 2022, 29 (03) : 2154 - 2164
  • [40] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
12345